Drug intelligence / Profile preview

CKDB-102

Development stage: Preclinical
Lead developer: CKD Bio
Modality: Small Molecules

Overview

CKDB-102 is an experimental antibiotic candidate being developed by CKD Bio, a South Korean pharmaceutical company specializing in the production of fermentation-based active pharmaceutical ingredients (APIs). Currently in the preclinical or early research and development (R&D) stage, CKDB-102 is part of the company's API sector pipeline focused on antimicrobial therapy. While the specific chemical class and mechanism of action remain proprietary, the drug is intended to address bacterial infections, potentially leveraging CKD Bio's expertise in fermentation technology for antibiotic production.

Beyond the preview

Go deeper on CKDB-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CKDB-102.

Explore the full profile